Why hip cartilage damage is hard to address — and why that is changing

Damaged cartilage in the hip does not heal. Unlike bone or soft tissue, articular cartilage has no blood supply of its own — so when a focal defect forms, whether from impact, sporting injury, or progressive wear, the body has no mechanism to repair it spontaneously. Left unaddressed, the damage typically worsens.

For most of the past two decades, meaningful cartilage intervention in the hip required surgery. The joint sits deep beneath layers of muscle and fat, making it inaccessible to the straightforward landmark-guided techniques that work in the knee. Patients who were not yet candidates for replacement often found themselves with limited options beyond pain management.

That picture has shifted. ChondroFiller® is a CE-marked injectable collagen scaffold that can be placed directly into the hip joint under real-time ultrasound guidance, in an outpatient clinic, without surgical incision or general anaesthetic. Understanding how it works — and why the hip can now be reached this way — starts with the scaffold itself.

How ChondroFiller works as a collagen scaffold

The product itself contains no living cells. ChondroFiller® is an acellular liquid composed of acid-extracted murine Type I collagen — purified structural protein, sterile, and free of donor cells. What it carries is architecture, not biology.

When the collagen liquid contacts the fluid environment inside the joint, it polymerises within minutes, forming a stable three-dimensional scaffold that fills and conforms to the defect. No heating, no mixing, no setting time beyond what happens naturally in situ.

The repair process then begins in four broad stages:

• Gelation — the scaffold sets and bonds to the surrounding cartilage and subchondral bone surface.
• Cell recruitment — the scaffold acts as a chemotactic signal, drawing the patient's own mesenchymal stem cells inward from the synovium and subchondral bone.
• Differentiation — once inside the matrix, those cells mature into chondrocyte-like cells and begin producing the collagen and proteoglycans that make up native cartilage tissue.
• Resorption — over the following months, the original collagen scaffold gradually breaks down and is replaced by the repair tissue the patient's own cells have laid down.

This process — acellular matrix-induced chondrogenesis — is meaningfully different from a lubricant or a space-filling gel. The injection does not substitute an inert material for lost cartilage; it provides a temporary framework that supports the body's own repair processes from within.

Why ultrasound guidance is essential for the hip

The hip is among the most anatomically demanding joints to inject accurately. Its capsule lies beneath the gluteal muscle mass, the tensor fasciae latae, and a variable depth of subcutaneous tissue — structures that make surface landmarks alone an unreliable guide for needle placement. In the knee, the joint line is close to the skin, the bony margins are palpable, and blind or landmark-guided injection carries an acceptable margin of error for many applications. The hip offers no equivalent shortcut: clinicians who rely on anatomical estimation rather than real-time imaging risk depositing material outside the joint capsule entirely.

Ultrasound guidance resolves this by allowing the clinician to track the needle continuously as it advances through soft tissue and to confirm correct intra-articular positioning before delivery. Fluoroscopic guidance — continuous X-ray tracking — provides an alternative, particularly useful when deep soft-tissue contrast is needed, though ultrasound has the advantage of visualising surrounding vessels and nerves simultaneously.

For ChondroFiller, placement accuracy determines whether the scaffold reaches the defect at all. An injection deposited outside the capsule cannot gel at the target site, regardless of the material's properties. Crucially, the injectable pathway demands none of the conditions required for arthroscopic implantation — no joint drying, no surgical portals, no theatre setting. Ultrasound guidance is precisely what makes accurate outpatient delivery viable in a joint this deep.

Operator experience with deep-joint injection is therefore a meaningful factor when choosing where to be assessed and treated.

Which patients are suitable for this approach

Suitability spans a wider spectrum than many patients expect. The injectable pathway is designed for two distinct groups: those with an isolated, focal Grade III or IV cartilage defect — an area of full-thickness damage surrounded by intact cartilage — and those with more widespread Kellgren-Lawrence Grade III or IV osteoarthritis, where the damage is diffuse rather than contained.

Age alone does not determine eligibility. There is no fixed upper limit, though biological response to the scaffold depends on overall joint health, the condition of surrounding tissue, and the depth and location of the defect — factors that vary between individuals at any age.

The 'bone on bone' finding on X-ray or MRI is often assumed to close the door on anything short of hip replacement. In practice, it does not automatically exclude assessment for ChondroFiller; joint mechanics, symptom profile, and what the patient is trying to achieve are all part of the picture, and some patients at this stage are assessed for ChondroFiller-led combination protocols as a joint-preservation pathway before committing to surgery.

What does determine suitability is a thorough clinical and imaging review. MRI findings, defect location, the quality of surrounding cartilage, and overall joint architecture all inform the decision — a self-assessment checklist cannot replicate that. The right starting point is a formal consultation where those variables can be properly evaluated.

What the appointment involves

Most of what happens on the day unfolds in under 45 minutes. The appointment takes place in an outpatient clinic and follows a clear sequence: a brief review of the imaging, local anaesthetic at the injection site, real-time ultrasound positioning of the needle, and delivery of the scaffold once intra-articular placement has been confirmed under direct visualisation.

The standard dose is 2.3 mL. For most patients, a single unit addresses the affected area adequately. Larger defects or multi-compartment hip disease — where damage spans more than one region of the joint — may require two or three units, delivered within the same appointment rather than across separate visits.

IV antibiotic cover is given as standard. Given the depth of the hip joint, this is a sensible precaution rather than an afterthought, and it forms part of the procedure itself rather than requiring a separate prescription or return visit.

What follows differs substantially from theatre-style recovery. There is no wound to dress and no requirement for assisted discharge or overnight monitoring. Most patients leave the clinic independently and can return to light daily activity relatively quickly; heavier loading of the hip is typically reintroduced gradually over the weeks that follow, guided by how the joint responds as the scaffold begins its repair process.

What outcomes evidence shows — and where the gaps are

Published clinical evidence for ChondroFiller follows a clear hierarchy, and understanding that hierarchy is the most useful thing a patient can take from the outcomes literature.

The strongest data come from knee cartilage studies. In multiple prospective series, IKDC scores — a validated patient-reported measure of joint function — improved by approximately 30 points at one year, well above the accepted minimum clinically important difference of 16.7 points. The Jerosch et al. post-market clinical follow-up study recorded a mean improvement of 32.4 points still present at three-year follow-up, with patients reaching a functional score of around 80 out of 100. Structural MRI adds a complementary layer: MOCART scores of 81.6 to 84.3 at twelve months indicate greater than 80% defect filling and good integration with surrounding native tissue. Scores progressed from 65.3 at four weeks to 81.6 at one year, confirming that the scaffold matures progressively rather than producing an acute short-term response.

For the hip specifically, published reporting references an improvement of approximately 30 points on the modified Harris Hip Score (mHHS) — a standard measure of hip function — though dedicated hip-outcome series are less numerous than the knee literature. MRI findings documented in wrist studies — including reduction in bone marrow oedema and visible widening of joint space — support the plausibility of cross-joint generalisation, given that the underlying scaffold mechanism is identical across sites. That generalisation nonetheless remains an extrapolation, and patients considering the hip pathway should treat it as such when weighing expected benefit.

Across published safety data, the complaint rate is approximately 0.06%, consistent with the tolerability profile of a guided outpatient procedure.

Taken together, the evidence positions ChondroFiller as a treatment capable of producing meaningful, durable functional improvement alongside measurable structural repair — not symptom relief alone. What it cannot yet confirm, with the same rigour as the knee evidence base, is the precise magnitude of that benefit in the hip across a large dedicated cohort. The honest clinical position is 'biologically plausible, mechanistically consistent, and clinically encouraging' — and that distinction should be part of any thorough pre-treatment assessment conversation.